Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk

NCT02702479 | Unknown

• 1 other identifier: CIHR-Surose vs HFCS
• Study Type: observational
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

The rise in high fructose corn syrup (HFCS) consumption over the past 40 years since its introduction as a popular sweetener in the United States has led to much concern regarding its contribution to the rise in obesity (1), diabetes (2) and related cardiometabolic disorders (3).Unlike sucrose which contains equal proportions of fructose and glucose bound by an α-glycosidic bond, HFCS contains 42-55% of fructose to glucose in a free (unbound) form (4). Despite these differences in composition, both sugars possess identical energy contribution on a gram to gram basis (4). However, the higher ratio of fructose to glucose in HFCS has led to the hypothesis that HFCS may uniquely contribute to cardiometabolic risk, more so than sucrose, through proposed differences in fructose metabolism, endocrine and hedonic properties (5). We will conduct a series of systematic reviews and meta-analyses to assess the role of HFCS versus sucrose under energy matched (isocaloric) conditions on cardiometabolic risk.

Conditions

Obesity; Dyslipidemia; Prediabetes; Dysglycemia; Gout; Hypertension; Non-Alcoholic Fatty Liver Disease; Cardiovascular Disease

Keywords

Systematic review and meta-analysis; Evidence-based medicine (EBM); Evidence-based nutrition (EBN); Clinical practice guidelines; Clinical trials; Dietary sugars; Fructose; High fructose corn syrup; Isocaloric; Hypercaloric; Cardiometabolic Risk Factors; Triglycerides; Cholesterol; Glycemic control; Body weight; Uric acid; Blood pressure; Fatty liver; Fasting; Postprandial

Outcome Measures

Primary Outcomes (7)

• Body weight and measures of adiposity analysis

  Up to 20 years

• Glycemic control analysis

  Up to 20 years

• Blood Lipids analysis

  Up to 20 years

• Blood pressure analysis

  Up to 20 years

• Uric acid analysis

  Up to 20 years

• Non-Alcoholic Fatty Liver Disease (NAFLD) and ectopic fat Analysis

  Up to 20 years

• Inflammation analysis

  Up to 20 years

Interventions

High Fructose Corn Syrup OTHER

An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet

Also known as: HFCS

Sucrose OTHER

An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet

Also known as: sugar

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All individuals, both children and adults, regardless of health status.

You may qualify if:

• Trials in humans
• Oral fructose-containing sugars intervention
• Presence of an adequate comparator in isocaloric substitution
• Diet duration \>=7 days
• Viable outcome data

You may not qualify if:

• Non-human trials
• Observational studies
• IV or parenteral fructose-containing sugars
• Lack of suitable comparator (i.e. a comparator arm not including sucrose or HFCS in isocaloric substitution)
• Diet duration \<7 days
• No viable outcome data

Sponsors & Collaborators

• University of Toronto: lead
• Canadian Institutes of Health Research (CIHR): collaborator
• The Physicians' Services Incorporated Foundation: collaborator
• Banting & Best Diabetes Centre: collaborator

Study Sites (1)

The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

Toronto, Ontario, M5C 2T2, Canada

Location

MeSH Terms

Conditions

Obesity; Dyslipidemias; Prediabetic State; Gout; Hypertension; Non-alcoholic Fatty Liver Disease; Cardiovascular Diseases; Body Weight; Fatty Liver; Fasting

Interventions

High Fructose Corn Syrup; Sucrose; Sugars

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Lipid Metabolism Disorders; Metabolic Diseases; Diabetes Mellitus; Glucose Metabolism Disorders; Endocrine System Diseases; Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Rheumatic Diseases; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Vascular Diseases; Liver Diseases; Digestive System Diseases; Feeding Behavior; Behavior

Intervention Hierarchy (Ancestors)

Dietary Sugars; Dietary Carbohydrates; Carbohydrates; Nutritive Sweeteners; Sweetening Agents; Flavoring Agents; Food Additives; Food Ingredients; Specialty Uses of Chemicals; Chemical Actions and Uses; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages; Disaccharides; Oligosaccharides; Polysaccharides

Study Officials

• John L Sievenpiper, MD,PhD,FRCPC

  University of Toronto

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: March 2, 2016
• First Posted: March 8, 2016
• Study Start: June 1, 2014
• Primary Completion: June 1, 2016
• Study Completion: June 1, 2016
• Last Updated: May 17, 2016

Record last verified: 2016-05

Locations

CA (1)